- Hyphens Pharma International (SGX:1J5)'s 1H23 revenue/net profit is in line with our projections, coming in at 51%/42% of our full-year forecast.
- Specialty Pharma Principals (SPP) 1H23 revenue experienced a drop of 12.9% y-o-y (- 27% y-o-y in 1Q23, 0% y-o-y in 2Q23) to S$42.0m on the back of
- - Read this at SGinvestors.io -
- shipping delays for specific products; and
- the absence of one-off tender awarded to Novem in 1H2022.
- Specialty Pharma Principals (SPP) 1H23 revenue experienced a drop of 12.9% y-o-y (- 27% y-o-y in 1Q23, 0% y-o-y in 2Q23) to S$42.0m on the back of
- Proprietary Brands (PB) 1H23 revenue rose 9.1% y-o-y to S$11.8m (+16% y-o-y in 1Q23, 3% y-o-y in 2Q23) fuelled by greater demand for Ceradan dermatological products and Ocean Health supplements.
- Medical Hypermart and Digital 1H23 revenue declined 3.5% y-o-y to S$20.9m.
Special dividend
- - Read this at SGinvestors.io -
Richer portfolio.
- Read more at SGinvestors.io.